2. Search Result
Search Result
Results for "

Bone+Resorption

" in MedChemExpress (MCE) Product Catalog:

120

Inhibitors & Agonists

2

Screening Libraries

3

Biochemical Assay Reagents

17

Peptides

6

Inhibitory Antibodies

29

Natural
Products

6

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P0090
    Calcitonin (salmon)
    2 Publications Verification

    Salmon calcitonin

    		 CGRP Receptor Cancer
    Calcitonin salmon, a calcium regulating hormone, is a dual-action amylin and calcitonin receptor agonist, could stimulate bone formation and inhibit bone resorption.
    Calcitonin (salmon)
  • HY-P2273
    Calcitonin (human)

    		CGRP Receptor Metabolic Disease
    Calcitonin (human) is a hypocalcemic hormone. Calcitonin can lower blood calcium levels and inhibit bone resorption. Calcitonin can be used in hypercalcemia or osteoporosis research .
    Calcitonin (human)
  • HY-P9958
    Denosumab
    2 Publications Verification

    AMG-162

    		 NF-κB Caspase Apoptosis RANKL/RANK Endocrinology Cancer
    Denosumab is a human monoclonal antibody that targets the protein RANKL. Denosumab binds to the receptor activator of nuclear factor kappa-B ligand (RANKL) and prevents its binding to the RANK receptor (KD of 0.003 nM for human RANKL). Denosumab promotes proliferation and spermatogenesis. Denosumab prevents bone resorption through inhibition of the NF-κB pathway. Denosumab can be used in bone-related studies .
    Denosumab
  • HY-B0631
    Alendronic acid
    Maximum Cited Publications
    10 Publications Verification

    		 NF-κB Interleukin Related Metabolic Disease
    Alendronate acid is an orally active bisphosphonate which binds to bone surfaces and inhibits bone resorption by osteoclasts. Alendronate acid induces skeletal alterations in the chicken embryonic development model. Alendronate acid can be used for osteoporosis research .
    Alendronic acid
  • HY-108685
    Alendronate sodium
    Maximum Cited Publications
    10 Publications Verification

    Alendronic acid monosodium salt

    		 NF-κB Interleukin Related Metabolic Disease
    Alendronate sodium is an orally active bisphosphonate which binds to bone surfaces and inhibits bone resorption by osteoclasts. Alendronate sodium induces skeletal alterations in the chicken embryonic development model. Alendronate sodium can be used for osteoporosis research .
    Alendronate sodium
  • HY-B0657A
    Clodronic acid disodium salt
    4 Publications Verification

    Clodronate disodium salt

    		 Apoptosis Metabolic Disease Cancer
    Clodronic acid (Clodronate) disodium salt is an orally active bisphosphonate. Clodronic acid disodium salt inhibits osteoclast-mediated bone resorption. Clodronic acid disodium salt reduces skeletal event risk in malignant bone disease, impairs malignant osteolysis, blocks bone matrix growth-factor release, induces apoptosis in osteoclasts and macrophages. Clodronic acid disodium salt is effective in the maintenance or improvement of bone mineral density. Clodronic acid disodium salt can be used for the research of multiple myeloma and postmenopausal osteoporosis .
    Clodronic acid disodium salt
  • HY-N0721
    Neoandrographolide
    1 Publications Verification

    Neoandrographiside

    		 ERK p38 MAPK JNK NF-κB PI3K PPAR GSK-3 CaMK NO Synthase Reactive Oxygen Species (ROS) Apoptosis Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Neoandrographolide is a diterpenoid compound isolated from Andrographis paniculata. Neoandrographolide inhibits osteoclasts differentiation and bone resorption through inhibition of MAPK/NF-κB/PI3K/AKT/GSK3β/PPAR/CAMK signaling pathway. Neoandrographolide inhibits apoptosis in rat embryonic ventricular cardiomyocytes. Neoandrographolide inhibits iNOS and the generation of ROS, activates eNOS, exhibiting anti-inflammatory and hypolipidemic activity .
    Neoandrographolide
  • HY-A0020
    Eldecalcitol
    4 Publications Verification

    ED-71; 2-(3-hydroxypropoxy)-1,25-dihydroxyvitamin D3

    		 VD/VDR Apoptosis Metabolic Disease Inflammation/Immunology Cancer
    Eldecalcitol (ED-71) is an orally active vitamin D3 analogue, inhibits bone resorption and increases bone mineral density. Eldecalcitol (ED-71) displays anti-tumor effect and inhibits cell proliferation, migration and induces apoptosis by suppressing GPx-1 .
    Eldecalcitol
  • HY-B0148
    Risedronic acid
    2 Publications Verification

    Risedronate

    		 Parasite Apoptosis Infection Metabolic Disease Cancer
    Risedronic acid (Risedronate) is a bisphosphonate and potent antiresorptive agent. Risedronic acid induces Apoptosis. Risedronic acid inhibits the transfer of farnesyl pyrophosphate groups to parasite proteins. Risedronic acid inhibits osteoclast-mediated bone resorption and alters bone metabolism. Risedronic acid inhibits blood-stage Plasmodium falciparum (IC50 of 20.3 μM) .
    Risedronic acid
  • HY-N2532
    Diphyllin
    3 Publications Verification

    		 VSV HIV Proton Pump Influenza Virus Infection Inflammation/Immunology Cancer
    Diphyllin is an orally active V-ATPase inhibitor (IC50=17 nM) and HIV-1 inhibitor (IC50=0.38 μM). Diphyllin blocks the acidification of osteoclast lysosomes and bone resorption lacunas (IC50=0.6 nM for acid influx inhibition)， thereby inhibiting bone resorption. Diphyllin can effectively inhibit osteoclast-mediated bone resorption and has no effect on osteoblastic bone formation. Diphyllin can be used in the research of bone metabolism-related diseases and has the potential to inhibit diseases related to excessive bone resorption .
    Diphyllin
  • HY-N0257
    Epimedin A
    4 Publications Verification

    		 PI3K Akt NF-κB NOD-like Receptor (NLR) Keap1-Nrf2 Heme Oxygenase (HO) SOD Caspase Interleukin Related Metabolic Disease Inflammation/Immunology
    Epimedin A, one of the main flavonoid active components in Herba Epimedii, is orally active. Epimedin A can inhibit osteoclastogenesis, differentiation, and bone resorption. Epimedin A also possesses anti-inflammatory activity. Epimedin A can be used in the research of osteoporosis and inflammatory diseases .
    Epimedin A
  • HY-B1246
    Thonzonium bromide
    5+ Cited Publications

    		 Bacterial Proton Pump Infection
    Thonzonium bromide is an antibacterial agent that is structurally similar to Farnesol (HY-Y0248A). Thonzonium bromide is also a monocationic surface-active agent, which inhibits RANKL-induced osteoclast formation and bone resorption in vitro and prevents LPS-induced bone loss in vivo. Thonzonium bromide inhibits proton transport in a dose-dependent manner (EC50=69 μM) .
    Thonzonium bromide
  • HY-110318
    VUF11207 fumarate
    3 Publications Verification

    		 CXCR Inflammation/Immunology Cancer
    VUF11207 fumarate is a CXCR7 agonist that binds specifically to CXCR7. VUF11207 fumarate reduces CXCL12-mediated osteoclastogenesis and bone resorption by inhibiting ERK phosphorylation .
    VUF11207 fumarate
  • HY-12398
    TEI-9647
    2 Publications Verification

    		 VD/VDR Metabolic Disease Inflammation/Immunology
    TEI-9647, a Vitamin D3 Lactone analogue, is a potent and specific vitamin D receptor (VDR) antagonist. TEI-9647 inhibits VDR/VDRE-mediated genomic actions of 1α,25(OH)2D3. TEI-9647 inhibits bone resorption and HL-60 cell differentiation induced by of 1α,25(OH)2D3. TEI-9647 has the potential for suppressing the excessive bone resorption and osteoclast formation in Paget's disease .
    TEI-9647
  • HY-N6084
    Humulone

    α-Lupulic acid

    		 COX GABA Receptor Apoptosis Cardiovascular Disease
    Humulone (α-Lupulic acid), a prenylated phloroglucinol derivative, is a potent cyclooxygenase-2 (COX-2) inhibitor. Humulone acts as a positive modulator of GABAA receptor at low micromolar concentrations. Humulone is an inhibitor of bone resorption. Humulone possesses antioxidant, anti-angiogenic and apoptosis-inducing properties .
    Humulone
  • HY-B0119
    Risedronic acid sodium
    2 Publications Verification

    Risedronate sodium

    		 Parasite Apoptosis Infection Metabolic Disease Cancer
    Risedronic acid (Risedronate) sodium, a bisphosphonate, is a potent anti-resorption agent that inhibits osteoclast-mediated bone resorption and changes the bone metabolism. Risedronic acid sodium suppresses osteoblast differentiation and induced caspase- and isoprenoid depletion-dependent apoptosis. Risedronic acid sodium inhibits blood stages of Plasmodium falciparum (IC50 of 20.3 μM). Risedronic acid sodium inhibits the transfer of the farnesyl pyrophosphate group to parasite proteins .
    Risedronic acid sodium
  • HY-N0094
    Ipriflavone
    2 Publications Verification

    		 Cytochrome P450 Metabolic Disease Cancer
    Ipriflavone is a synthetic isoflavone derivative used to suppress bone resorption.
    Ipriflavone
  • HY-114275
    Justicidin B

    		Fungal Parasite Apoptosis Infection Cardiovascular Disease Cancer
    Justicidin B is a potent anticancer lignan and proapoptotic agent. Justicidin B is also a bone resorption inhibitor, and has strong antiviral, fungicidal, antiprotozoal effects. Justicidin B significantly inhibits platelet aggregation .
    Justicidin B
  • HY-B2162B
    Chondroitin sulfate sodium (from bovine)

    Chondroitin polysulfate sodium (from bovine)

    		 Reactive Oxygen Species (ROS) Endogenous Metabolite Inflammation/Immunology
    Chondroitin sulfate (Chondroitin polysulfate) sodium (from bovine)) is a sulfated linear polysaccharide extracted from bovine sources, belonging to glycosaminoglycans. Chondroitin sulfate sodium (from bovine) inhibits osteoclast-mediated bone resorption and exhibits antioxidant activity, which is negatively correlated with molecular weight. Chondroitin sulfate sodium (from bovine) can be used in studies related to osteoarthritis .
    Chondroitin sulfate sodium (from bovine)
  • HY-17397
    Strontium Ranelate
    2 Publications Verification

    Distrontium renelate; S12911

    		 CaSR Metabolic Disease
    Strontium Ranelate (S12911) is an antiosteoporotic agent that acts by reducing bone resorption and promoting bone formation, thereby inducing a positive bone balance. Strontium Ranelate can also activate the calcium-sensing receptor (CaSR) in non skeletal cells, resulting in the activation of inositol 1, 4, 5-triphosphate production and mitogen-activated protein kinase signaling .
    Strontium Ranelate
  • HY-108059
    β-Cryptoxanthin

    (3R)-β-Cryptoxanthin

    		 Drug Derivative Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    β-Cryptoxanthin ((3R)-β-Cryptoxanthin) is an orally active carotenoid found in fruits and vegetables such as angerines, red peppers, and pumpkin. β-Cryptoxanthin inhibits prevents osteoclast formation and inhibits bone resorption. β-Cryptoxanthin maintains retinol status in vivo. β-cryptoxanthin shows anti-inflammation and anticancer activity. β-Cryptoxanthin can be used for the researches of osteoporosis and bladder carcer .
    β-Cryptoxanthin
  • HY-103352
    L-006235

    L-235

    		 Cathepsin Metabolic Disease
    L-006235 (L-235) is a potent, selective, reversible and orally active inhibitor of cathepsin K, with an IC50 of 5 nM in bone resorption assay. L-006235 shows selectivity for cathepsin K (Ki=0.2 nM) over cathepsin B, cathepsin L, and cathepsin S (Ki=1, 6, and 47 μM, respectively). L-006235 can reduce collagen degradation and prevent bone loss .
    L-006235
  • HY-P9958A
    Denosumab (anti-TNFSF11)
    2 Publications Verification

    		 RANKL/RANK Apoptosis NF-κB Neurological Disease Endocrinology Cancer
    Denosumab (anti-TNFSF11) is a human monoclonal antibody that targets the protein RANKL. Denosumab binds to the receptor activator of nuclear factor kappa-B ligand (RANKL) and prevents its binding to the RANK receptor (KD of 0.003 nM for human RANKL). Denosumab promotes proliferation and spermatogenesis. Denosumab prevents bone resorption through inhibition of the NF-κB pathway. Denosumab can be used in bone-related studies .
    Denosumab (anti-TNFSF11)
  • HY-10294
    Relacatib

    SB-462795

    		 Cathepsin Metabolic Disease Cancer
    Relacatib (SB-462795) is a novel, potent, and orally active inhibitor of human cathepsins K, L, and V with Ki values of 41 pM, 68 pM, and 53 pM, respectively. Relacatib inhibits endogenous cathepsin K in situ in human osteoclasts and human osteoclast-mediated bone resorption with IC50 values of 45 nM and 70 nM, respectively. Relacatib inhibits bone resorption in vitro in human tissue as well as in cynomolgus monkeys in vivo .
    Relacatib
  • HY-N1956
    Rubiadin-1-methyl ether
    1 Publications Verification

    		 NF-κB Metabolic Disease
    Rubiadin-1-methyl ether is a natural anthraquinone isolated from Morinda officinalis How, and inhibits osteoclastic bone resorption via inhibition on the phosphorylation of NF-κB p65 and the degradation of IκBα as well as decrease in the nuclear translocation of p65 .
    Rubiadin-1-methyl ether
  • HY-P1189
    Echistatin

    		Integrin Metabolic Disease Inflammation/Immunology
    Echistatin, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation. Echistatin is a potent inhibitor of bone resorption in culture. Echistatin is a potent antagonist of αIIbβ3, αvβ3 and α5β1 .
    Echistatin
  • HY-B0657
    Clodronic acid
    4 Publications Verification

    Clodronate

    		 Apoptosis Metabolic Disease Cancer
    Clodronic acid (Clodronate) is an orally active bisphosphonate. Clodronic acid inhibits osteoclast-mediated bone resorption. Clodronic acid reduces skeletal event risk in malignant bone disease, impairs malignant osteolysis, blocks bone matrix growth-factor release, induces apoptosis in osteoclasts and macrophages. Clodronic acid is effective in the maintenance or improvement of bone mineral density. Clodronic acid can be used for the research of multiple myeloma and postmenopausal osteoporosis .
    Clodronic acid
  • HY-N10117
    2,3-Bis(3-indolylmethyl)indole

    		RANKL/RANK Others
    2,3-Bis(3-indolylmethyl)indole significantly suppresses RANKL-induced osteoclast formation, actin ring formation, and bone resorption in a concentration-dependent manner.
    2,3-Bis(3-indolylmethyl)indole
  • HY-N9331
    Cimicifugoside H-1

    Cimicidanol-3-O-β-d-xyloside

    		 Others Metabolic Disease
    Cimicifugoside H-1, a cyclolanostanol xyloside, is a major constituent of C. foetida L. extract. Cimicifugoside H-1 inhibits bone resorption and ovariectomy-induced bone loss .
    Cimicifugoside H-1
  • HY-P1189A
    Echistatin TFA

    		Integrin Metabolic Disease Inflammation/Immunology
    Echistatin TFA, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation. Echistatin is a potent inhibitor of bone resorption in culture. Echistatin is a potent antagonist of αIIbβ3, αvβ3 and α5β1 .
    Echistatin TFA
  • HY-N1746
    (2S)-2'-Methoxykurarinone

    2'-O-Methylkurarinone

    		 RANKL/RANK Metabolic Disease Inflammation/Immunology Cancer
    (2S)-2'-Methoxykurarinone, a compound isolated from the roots of Sophora flavescens, has anti-inflammatory, antipyretic, antidiabetic, and antineoplastic effects. (2S)-2'-Methoxykurarinone (MK) inhibits osteoclastogenesis and bone resorption through down-regulation of RANKL signaling. (2S)-2'-Methoxykurarinone (MK) displays cytotoxic activity against human myeloid leukemia HL-60 cells .
    (2S)-2'-Methoxykurarinone
  • HY-B0515B
    Ibandronate Sodium
    1 Publications Verification

    		 Apoptosis Metabolic Disease Cancer
    Ibandronate Sodium is an orally active, selective inhibitor of farnesyl pyrophosphate synthase (FPP synthase). Ibandronate Sodium can block the mevalonate pathway to inhibit the isoprenylation modification of small GTPases (such as RAS, RHO family proteins), induce tumor cell apoptosis and inhibit bone resorption. Ibandronate Sodium inhibits tumor cell proliferation (such as ER+ breast cancer cells), promotes the expression of the pro-apoptotic gene FAS, and can produce synergistic anti-tumor effects with anti-estrogen compounds. Ibandronate Sodium is used in the study of osteoporosis and bone metastatic tumors (such as breast cancer bone metastasis) .
    Ibandronate Sodium
  • HY-16322
    Minodronic acid
    1 Publications Verification

    YM-529

    		 P2X Receptor Apoptosis Farnesyl Transferase Metabolic Disease Cancer
    Minodronic acid (YM-529) is an FPP synthase inhibitor with an IC50 of 3 nM, and also an antagonist of P2X2/3 receptors with an IC50 of 62.7 μM. Minodronic acid induces tumor cell apoptosis and inhibits cell growth. Minodronic acid also suppresses bone resorption. Minodronic acid can be used in research related to osteoporosis and cancer .
    Minodronic acid
  • HY-16322A
    Minodronic acid hydrate
    1 Publications Verification

    YM-529 hydrate

    		 P2X Receptor Apoptosis Metabolic Disease Cancer
    Minodronic acid (YM-529) hydrate is an FPP synthase inhibitor with an IC50 of 3 nM, and also an antagonist of P2X2/3 receptors with an IC50 of 62.7 μM. Minodronic acid hydrate induces tumor cell apoptosis and inhibits cell growth. Minodronic acid hydrate also suppresses bone resorption. Minodronic acid hydrate can be used in research related to osteoporosis and cancer .
    Minodronic acid hydrate
  • HY-N14323
    Madindoline A

    		Interleukin Related STAT Metabolic Disease
    Madindoline A is an orally active gp130 antagonist with a KD of 288 μM. Madindoline A inhibits IL-6- and IL-11-induced osteoclastogenesis, suppresses IL-6-stimulated serum amyloid A protein production, inhibits bone resorption and bone loss, and also inhibits IL-6- and IL-11-dependent cell line growth, as well as IL-6-dependent Stat3 tyrosine phosphorylation. Madindoline A is applicable for the research of hormone-dependent postmenopausal osteoporosis .
    Madindoline A
  • HY-113230B
    Galactosylhydroxylysine hydrochloride
    1 Publications Verification

    		 Endogenous Metabolite Metabolic Disease
    Galactosylhydroxylysine hydrochloride is a component of bone collagen produced by post-translational glycosylation of hydroxylysine. Galactosylhydroxylysine hydrochloride is released during bone resorption and has been shown to be elevated in metabolic bone loss .
    Galactosylhydroxylysine hydrochloride
  • HY-N7646
    Curculigoside B

    		Others Others
    Curculigoside B, a phenolic glycoside isolated from Curculigo orchioides, enhances the osteoblast proliferation, decreases the area of bone resorption pit, osteoclastic formation and TRAP activity. Antiosteoporotic and antioxidative activities .
    Curculigoside B
  • HY-P1418A
    DPC-AJ1951 TFA

    		Thyroid Hormone Receptor Endocrinology
    DPC-AJ1951 TFA, a 14 amino acid peptide that acts as a potent agonist of the parathyroid hormone (PTH)/PTH-related peptide receptor (PPR). And characterized the activity of DPC-AJ1951 TFA in ex vivo and in vivo assays of bone resorption .
    DPC-AJ1951 TFA
  • HY-123370
    FR-167356

    		Proton Pump Metabolic Disease Cancer
    FR-167356 is a potent, orally active and selective vacuolar ATPase inhibitor with IC50 values of 170, 220, 370, and 1200 nM for osteoclast plasma membranes, macrophage microsomes, renal brush border membranes, and liver lysosomal membranes, respectively. FR-167356 inhibits bone resorption and ovariectomy-induced bone loss .
    FR-167356
  • HY-149149
    Incadronic acid

    		Bacterial Infection Metabolic Disease Cancer
    Incadronic acid inhibits growth of Dictyostelium discoideum with an IC50 of 1.6 μM. Incadronic acid binds the farnesyl diphosphate synthase (FPPS) in Leishmania major with the Ki of 23 nM. Incadronic acid inhibits the bone resorption and reduces bone loss, that can be used in osteoporosis research. Incadronic acid inhibits the proliferation of cells RAW264.7, PC-3 and MCF-7 with IC50 of 48 to 228.6 µM .
    Incadronic acid
  • HY-B2097
    Incadronate disodium

    YM 175; Bisphonal

    		 Farnesyl Transferase Metabolic Disease
    Incadronate disodium (YM 175) is a bisphosphonate with strong inhibitory activity on bone resorption. Incadronate disodium indirectly stimulates renal 25-hydroxyvitamin D-1-hydroxylase by increasing circulating parathyroid hormone. Incadronate disodium, a cholesterol-lowering agent, is a potent inhibitor of rat liver microsomal squalene synthase (Ki=57 nM). Incadronate disodium inhibits sterol biosynthesis in mouse macrophage J774 cells (IC50=64 μM). Incadronate disodium has the potential for malignant tumors research .
    Incadronate disodium
  • HY-N5023
    Veraguensin

    		Others Metabolic Disease
    Veraguensin is a lignan compound derived from Magnolia sp.. Veraguensin can inhibit bone resorption
    Veraguensin
  • HY-P0284
    C-telopeptide

    		MMP Inflammation/Immunology
    C-telopeptide, a cross-linked peptide of type I collagen, is released during bone resorption and has been correlated with bone mineral density (BMD).
    C-telopeptide
  • HY-P0284A
    C-telopeptide TFA

    		MMP Inflammation/Immunology
    C-telopeptide TFA, a cross-linked peptide of type I collagen, is released during bone resorption and has been correlated with bone mineral density (BMD) .
    C-telopeptide TFA
  • HY-P1288
    Protein Kinase C (530-558)

    PKC fragment (530-558)

    		 PKC Others
    Protein Kinase C (530-558), a peptide fragment of protein kinase C (PKC), is a potent PKC activator. Protein Kinase C (530-558) significantly inhibits osteoclastic bone resorption .
    Protein Kinase C (530-558)
  • HY-P4798
    Osteostatin (1-5) amide (human, bovine, dog, horse, mouse, rabbit, rat)

    Human PTHrP(107-111) amide

    		 PTHR Others
    Osteostatin (1-5) amide (human, bovine, dog, horse, mouse, rabbit, rat) (Human PTHrP (107-111) amide) is a C-terminal parathyroid hormone-related protein fragment that can inhibit bone resorption .
    Osteostatin (1-5) amide (human, bovine, dog, horse, mouse, rabbit, rat)
  • HY-B0631S
    Alendronic acid-d6

    		Isotope-Labeled Compounds Cancer
    Alendronic acid-d6 is the deuterium labeled Alendronic acid. Alendronic acid, a bisphosphonate, is a farnesyl diphosphate synthase (FDPS) inhibitor. Alendronic acid inhibits osteoclast-mediated bone resorption. Alendronic acid shows efficacy in postmenopausal osteoporosis, malignant hypercalcemia and Paget’s disease .
    Alendronic acid-d6
  • HY-129337
    Reveromycin A

    		Antibiotic Fungal Apoptosis Infection Cancer
    Reveromycin A, a benzoquinoid antibiotic isolated from the genus Streptomyces, is a selective inhibitor of protein synthesis in eukaryotic cells. Reveromycin A inhibits bone resorption by inducing apoptosis specifically in osteoclasts. Reveromycin A has antiproliferative activity against tumor cell lines and antifungal activity .
    Reveromycin A
  • HY-50887
    L-873724

    		Cathepsin Metabolic Disease
    L-873724 is a potent, orally bioavailable, selective and reversible non-basic cathepsin K inhibitor, with IC50s of 0.2, 178, 264, and 5239 nM for cathepsin K, cathepsin S, cathepsin L, cathepsin B, respectively . L-873724 also exhibits an IC50 of 0.5 nM for rabbit cathepsin K. L-873724 inhibits bone resorption .
    L-873724
  • HY-W107722
    IN04

    		LRRK2 Endocrinology
    IN04 is a inhibitor of leucine-rich repeat kinase 1 (LRRK1). IN04 can completely block the binding of ATP to the human LRRK1 kinase domain, thereby inhibiting the kinase activity of LRRK1. IN04 can significantly impair the bone resorption ability of osteoclasts, with an IC50 value of 5.72 μM. IN04 can be used for the study of osteoporosis .
    IN04

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: